Randomized trial tested THC, CBD, and their combination for peripheral neuropathic pain
A four-arm randomized, double-blind trial compared oral CBD, THC, their combination, and placebo for peripheral neuropathic pain, providing rigorous head-to-head data on individual and combined cannabinoid effects.
Quick Facts
What This Study Found
The trial compared four conditions (CBD alone, THC alone, CBD/THC combination, and placebo) for neuropathic pain. Results provide controlled evidence on whether CBD, THC, or their combination offers meaningful pain relief in this population.
Key Numbers
Four treatment arms with 1:1:1:1 randomization: CBD, THC, CBD/THC combination, and placebo. Oral capsule formulation for peripheral neuropathic pain.
How They Did This
Randomized, double-blind, placebo-controlled trial with four arms (1:1:1:1 ratio): CBD capsules, THC capsules, CBD/THC combination capsules, and placebo. Patients with peripheral neuropathic pain enrolled.
Why This Research Matters
Cannabinoids are often prescribed for neuropathic pain despite weak evidence. This four-arm design directly compares individual cannabinoids, their combination, and placebo, providing the type of data clinical guidelines require.
The Bigger Picture
Evidence-based guidelines currently give cannabinoids a "weak against" recommendation for neuropathic pain. Rigorous trials like this one either support or challenge that assessment and could shift clinical practice.
What This Study Doesn't Tell Us
Oral capsules may produce different effects than smoked or vaporized cannabis. Specific doses tested may not reflect optimal dosing. Sample size determines the power to detect differences between arms. Duration of treatment may affect conclusions.
Questions This Raises
- ?Is the CBD/THC combination more effective than either alone?
- ?Does the route of administration (oral vs. inhaled) significantly affect neuropathic pain outcomes?
Trust & Context
- Key Stat:
- Four-arm double-blind trial: CBD vs. THC vs. combination vs. placebo for neuropathic pain
- Evidence Grade:
- Randomized, double-blind, placebo-controlled trial with a robust four-arm design. High-quality evidence regardless of outcome direction.
- Study Age:
- Published 2023.
- Original Title:
- Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment.
- Published In:
- European journal of pain (London, England), 27(4), 492-506 (2023)
- Authors:
- Zubcevic, Kanita, Petersen, Merete, Bach, Flemming Winther, Heinesen, Aksel, Enggaard, Thomas Peter, Almdal, Thomas Peter, Holbech, Jakob Vormstrup, Vase, Lene, Jensen, Troels Stahelin, Hansen, Christian Stevns, Finnerup, Nanna Brix, Sindrup, Søren H
- Database ID:
- RTHC-05056
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does cannabis help neuropathic pain?
This rigorous trial tested THC, CBD, and their combination against placebo specifically for peripheral neuropathic pain. The four-arm design allows direct comparison of individual cannabinoids and their combination. Current evidence-based guidelines give only weak support for cannabinoids in neuropathic pain.
Is THC or CBD better for nerve pain?
This trial directly addresses that question by comparing each cannabinoid individually and in combination against placebo. Previous evidence has been inconsistent, and this head-to-head comparison with controlled oral dosing provides more definitive data.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05056APA
Zubcevic, Kanita; Petersen, Merete; Bach, Flemming Winther; Heinesen, Aksel; Enggaard, Thomas Peter; Almdal, Thomas Peter; Holbech, Jakob Vormstrup; Vase, Lene; Jensen, Troels Stahelin; Hansen, Christian Stevns; Finnerup, Nanna Brix; Sindrup, Søren H. (2023). Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment.. European journal of pain (London, England), 27(4), 492-506. https://doi.org/10.1002/ejp.2072
MLA
Zubcevic, Kanita, et al. "Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment.." European journal of pain (London, 2023. https://doi.org/10.1002/ejp.2072
RethinkTHC
RethinkTHC Research Database. "Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (..." RTHC-05056. Retrieved from https://rethinkthc.com/research/zubcevic-2023-oral-capsules-of-tetrahydrocannabinol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.